# Zoom Communications, Inc.: financial statements, quarterly ZM · Nasdaq · CIK 1585521 · [Technology](/sectors/technology.md) · fiscal year ends Jan 31 Pages: [Overview](/companies/zm.md) · [Financials](/companies/zm/financials.md) · [Filings](/companies/zm/filings.md) · [Insiders](/companies/zm/insiders.md) Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/zm/financials.md?period=annual). ## Income statement | Line item | Unit | Q3 FY2024 (2023-10-31) | Q4 FY2024 (2024-01-31) | Q1 FY2025 (2024-04-30) | Q2 FY2025 (2024-07-31) | Q3 FY2025 (2024-10-31) | Q4 FY2025 (2025-01-31) | Q1 FY2026 (2025-04-30) | Q2 FY2026 (2025-07-31) | Q3 FY2026 (2025-10-31) | Q4 FY2026 (2026-01-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Revenue | $m | [1,137](/filings/0001585521-24-000260.md) | [1,146 d](/filings/0001585521-26-000030.md) | [1,141](/filings/0001585521-25-000090.md) | [1,163](/filings/0001585521-25-000141.md) | [1,178](/filings/0001585521-25-000202.md) | [1,184 d](/filings/0001585521-26-000030.md) | [1,175](/filings/0001585521-26-000071.md) | [1,217](/filings/0001585521-26-000121.md) | [1,230](/filings/0001585521-25-000202.md) | [1,247 d](/filings/0001585521-26-000030.md) | [1,239](/filings/0001585521-26-000071.md) | [1,277](/filings/0001585521-26-000121.md) | | Cost of revenue | $m | [271](/filings/0001585521-24-000260.md) | [276 d](/filings/0001585521-26-000030.md) | [273](/filings/0001585521-25-000090.md) | [285](/filings/0001585521-25-000141.md) | [284](/filings/0001585521-25-000202.md) | [287 d](/filings/0001585521-26-000030.md) | [278](/filings/0001585521-26-000071.md) | [273](/filings/0001585521-26-000121.md) | [272](/filings/0001585521-25-000202.md) | [296 d](/filings/0001585521-26-000030.md) | [274](/filings/0001585521-26-000071.md) | [292](/filings/0001585521-26-000121.md) | | Gross profit | $m | [866](/filings/0001585521-24-000260.md) | [870 d](/filings/0001585521-26-000030.md) | [868](/filings/0001585521-25-000090.md) | [877](/filings/0001585521-25-000141.md) | [894](/filings/0001585521-25-000202.md) | [897 d](/filings/0001585521-26-000030.md) | [896](/filings/0001585521-26-000071.md) | [944](/filings/0001585521-26-000121.md) | [958](/filings/0001585521-25-000202.md) | [951 d](/filings/0001585521-26-000030.md) | [965](/filings/0001585521-26-000071.md) | [985](/filings/0001585521-26-000121.md) | | Research and development | $m | [197](/filings/0001585521-24-000260.md) | [205 d](/filings/0001585521-26-000030.md) | [206](/filings/0001585521-25-000090.md) | [207](/filings/0001585521-25-000141.md) | [223](/filings/0001585521-25-000202.md) | [217 d](/filings/0001585521-26-000030.md) | [205](/filings/0001585521-26-000071.md) | [206](/filings/0001585521-26-000121.md) | [210](/filings/0001585521-25-000202.md) | [223 d](/filings/0001585521-26-000030.md) | [228](/filings/0001585521-26-000071.md) | [242](/filings/0001585521-26-000121.md) | | Operating income | $m | [169](/filings/0001585521-24-000260.md) | [169 d](/filings/0001585521-26-000030.md) | [203](/filings/0001585521-25-000090.md) | [202](/filings/0001585521-25-000141.md) | [183](/filings/0001585521-25-000202.md) | [225 d](/filings/0001585521-26-000030.md) | [242](/filings/0001585521-26-000071.md) | [322](/filings/0001585521-26-000121.md) | [310](/filings/0001585521-25-000202.md) | [250 d](/filings/0001585521-26-000030.md) | [310](/filings/0001585521-26-000071.md) | [314](/filings/0001585521-26-000121.md) | | Income tax | $m | [44.6](/filings/0001585521-24-000260.md) | [54.1 d](/filings/0001585521-26-000030.md) | [75.7](/filings/0001585521-25-000090.md) | [73.9](/filings/0001585521-25-000141.md) | [73.4](/filings/0001585521-25-000202.md) | [82.5 d](/filings/0001585521-26-000030.md) | [61.2](/filings/0001585521-26-000071.md) | [89.6](/filings/0001585521-26-000121.md) | [182](/filings/0001585521-25-000202.md) | [190 d](/filings/0001585521-26-000030.md) | [106](/filings/0001585521-26-000071.md) | [453](/filings/0001585521-26-000121.md) | | Net income | $m | [141](/filings/0001585521-24-000260.md) | [299 d](/filings/0001585521-26-000030.md) | [216](/filings/0001585521-25-000090.md) | [219](/filings/0001585521-25-000141.md) | [207](/filings/0001585521-25-000202.md) | [368 d](/filings/0001585521-26-000030.md) | [255](/filings/0001585521-26-000071.md) | [359](/filings/0001585521-26-000121.md) | [613](/filings/0001585521-25-000202.md) | [674 d](/filings/0001585521-26-000030.md) | [426](/filings/0001585521-26-000071.md) | [1,542](/filings/0001585521-26-000121.md) | | Diluted EPS | $ per share | [0.45](/filings/0001585521-24-000260.md) | not reported | [0.69](/filings/0001585521-25-000090.md) | [0.70](/filings/0001585521-25-000141.md) | [0.66](/filings/0001585521-25-000202.md) | not reported | [0.81](/filings/0001585521-26-000071.md) | [1.16](/filings/0001585521-26-000121.md) | [2.01](/filings/0001585521-25-000202.md) | not reported | [1.42](/filings/0001585521-26-000071.md) | [5.15](/filings/0001585521-26-000121.md) | | Basic EPS | $ per share | [0.47](/filings/0001585521-24-000260.md) | not reported | [0.70](/filings/0001585521-25-000090.md) | [0.71](/filings/0001585521-25-000141.md) | [0.67](/filings/0001585521-25-000202.md) | not reported | [0.84](/filings/0001585521-26-000071.md) | [1.19](/filings/0001585521-26-000121.md) | [2.05](/filings/0001585521-25-000202.md) | not reported | [1.45](/filings/0001585521-26-000071.md) | [5.27](/filings/0001585521-26-000121.md) | - Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax - Cost of revenue: us-gaap:CostOfGoodsAndServicesSold - Gross profit: us-gaap:GrossProfit - Research and development: us-gaap:ResearchAndDevelopmentExpense - Operating income: us-gaap:OperatingIncomeLoss - Income tax: us-gaap:IncomeTaxExpenseBenefit - Net income: us-gaap:NetIncomeLoss - Diluted EPS: us-gaap:EarningsPerShareDiluted - Basic EPS: us-gaap:EarningsPerShareBasic ## Balance sheet | Line item | Unit | Q3 FY2024 (2023-10-31) | FY2024 (2024-01-31) | Q1 FY2025 (2024-04-30) | Q2 FY2025 (2024-07-31) | Q3 FY2025 (2024-10-31) | FY2025 (2025-01-31) | Q1 FY2026 (2025-04-30) | Q2 FY2026 (2025-07-31) | Q3 FY2026 (2025-10-31) | FY2026 (2026-01-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Cash and equivalents | $bn | [1.5](/filings/0001585521-24-000260.md) | [1.6](/filings/0001585521-26-000030.md) | [1.9](/filings/0001585521-25-000090.md) | [1.5](/filings/0001585521-25-000141.md) | [1.3](/filings/0001585521-25-000202.md) | [1.3](/filings/0001585521-26-000030.md) | [1.2](/filings/0001585521-26-000071.md) | [1.2](/filings/0001585521-26-000121.md) | [1.2](/filings/0001585521-25-000202.md) | [1.3](/filings/0001585521-26-000121.md) | [0.9](/filings/0001585521-26-000071.md) | [0.9](/filings/0001585521-26-000121.md) | | Current assets | $bn | [7.5](/filings/0001585521-23-000249.md) | [7.9](/filings/0001585521-25-000042.md) | [8.3](/filings/0001585521-24-000094.md) | [8.4](/filings/0001585521-24-000181.md) | [8.5](/filings/0001585521-24-000260.md) | [8.7](/filings/0001585521-26-000030.md) | [8.7](/filings/0001585521-25-000090.md) | [8.7](/filings/0001585521-25-000141.md) | [8.7](/filings/0001585521-25-000202.md) | [8.7](/filings/0001585521-26-000121.md) | [8.6](/filings/0001585521-26-000071.md) | [8.1](/filings/0001585521-26-000121.md) | | Total assets | $bn | [9.3](/filings/0001585521-23-000249.md) | [9.9](/filings/0001585521-25-000042.md) | [10.3](/filings/0001585521-24-000094.md) | [10.5](/filings/0001585521-24-000181.md) | [10.7](/filings/0001585521-24-000260.md) | [11.0](/filings/0001585521-26-000030.md) | [11.0](/filings/0001585521-25-000090.md) | [11.0](/filings/0001585521-25-000141.md) | [11.4](/filings/0001585521-25-000202.md) | [12.0](/filings/0001585521-26-000121.md) | [12.2](/filings/0001585521-26-000071.md) | [13.6](/filings/0001585521-26-000121.md) | | Current liabilities | $bn | [1.8](/filings/0001585521-23-000249.md) | [1.8](/filings/0001585521-25-000042.md) | [1.9](/filings/0001585521-24-000094.md) | [1.8](/filings/0001585521-24-000181.md) | [1.9](/filings/0001585521-24-000260.md) | [1.9](/filings/0001585521-26-000030.md) | [1.9](/filings/0001585521-25-000090.md) | [1.9](/filings/0001585521-25-000141.md) | [2.0](/filings/0001585521-25-000202.md) | [2.0](/filings/0001585521-26-000121.md) | [2.0](/filings/0001585521-26-000071.md) | [2.1](/filings/0001585521-26-000121.md) | | Total liabilities | $bn | [1.9](/filings/0001585521-23-000249.md) | [1.9](/filings/0001585521-25-000042.md) | [2.0](/filings/0001585521-24-000094.md) | [2.0](/filings/0001585521-24-000181.md) | [2.0](/filings/0001585521-24-000260.md) | [2.1](/filings/0001585521-26-000030.md) | [2.0](/filings/0001585521-25-000090.md) | [2.1](/filings/0001585521-25-000141.md) | [2.1](/filings/0001585521-25-000202.md) | [2.2](/filings/0001585521-26-000121.md) | [2.2](/filings/0001585521-26-000071.md) | [2.3](/filings/0001585521-26-000121.md) | | Shareholders' equity | $bn | [7.4](/filings/0001585521-24-000260.md) | [8.0](/filings/0001585521-26-000030.md) | [8.3](/filings/0001585521-25-000141.md) | [8.5](/filings/0001585521-25-000202.md) | [8.7](/filings/0001585521-25-000202.md) | [8.9](/filings/0001585521-26-000121.md) | [8.9](/filings/0001585521-26-000121.md) | [9.0](/filings/0001585521-26-000121.md) | [9.3](/filings/0001585521-25-000202.md) | [9.8](/filings/0001585521-26-000121.md) | [10.0](/filings/0001585521-26-000121.md) | [11.3](/filings/0001585521-26-000121.md) | - Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue - Current assets: us-gaap:AssetsCurrent - Total assets: us-gaap:Assets - Current liabilities: us-gaap:LiabilitiesCurrent - Total liabilities: us-gaap:Liabilities - Shareholders' equity: us-gaap:StockholdersEquity ## Cash flow | Line item | Unit | Q3 FY2024 (2023-10-31) | Q4 FY2024 (2024-01-31) | Q1 FY2025 (2024-04-30) | Q2 FY2025 (2024-07-31) | Q3 FY2025 (2024-10-31) | Q4 FY2025 (2025-01-31) | Q1 FY2026 (2025-04-30) | Q2 FY2026 (2025-07-31) | Q3 FY2026 (2025-10-31) | Q4 FY2026 (2026-01-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Operating cash flow | $m | [493 d](/filings/0001585521-24-000260.md) | [351 d](/filings/0001585521-26-000030.md) | [588](/filings/0001585521-25-000090.md) | [449 d](/filings/0001585521-25-000141.md) | [483 d](/filings/0001585521-25-000202.md) | [425 d](/filings/0001585521-26-000030.md) | [489](/filings/0001585521-26-000071.md) | [516 d](/filings/0001585521-26-000121.md) | [629 d](/filings/0001585521-25-000202.md) | [355 d](/filings/0001585521-26-000030.md) | [522](/filings/0001585521-26-000071.md) | [495 d](/filings/0001585521-26-000121.md) | | Capital expenditure | $m | [40.0 d](/filings/0001585521-24-000260.md) | [18.5 d](/filings/0001585521-26-000030.md) | [18.5](/filings/0001585521-25-000090.md) | [84.2 d](/filings/0001585521-25-000141.md) | [25.5 d](/filings/0001585521-25-000202.md) | [8.3 d](/filings/0001585521-26-000030.md) | [25.9](/filings/0001585521-26-000071.md) | [8.0 d](/filings/0001585521-26-000121.md) | [15.0 d](/filings/0001585521-25-000202.md) | [16.1 d](/filings/0001585521-26-000030.md) | [21.1](/filings/0001585521-26-000071.md) | [22.4 d](/filings/0001585521-26-000121.md) | | Share repurchases | $m | [0.0 d](/filings/0001585521-24-000260.md) | [0.0 d](/filings/0001585521-26-000030.md) | [150](/filings/0001585521-25-000090.md) | [288 d](/filings/0001585521-25-000141.md) | [302 d](/filings/0001585521-25-000202.md) | [355 d](/filings/0001585521-26-000030.md) | [418](/filings/0001585521-26-000071.md) | [465 d](/filings/0001585521-26-000121.md) | [414 d](/filings/0001585521-25-000202.md) | [324 d](/filings/0001585521-26-000030.md) | [362](/filings/0001585521-26-000071.md) | [361 d](/filings/0001585521-26-000121.md) | - Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities - Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment - Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock ## Shares | Line item | Unit | Q3 FY2023 (2022-10-31) | Q1 FY2024 (2023-04-30) | Q2 FY2024 (2023-07-31) | Q3 FY2024 (2023-10-31) | Q1 FY2025 (2024-04-30) | Q2 FY2025 (2024-07-31) | Q3 FY2025 (2024-10-31) | Q1 FY2026 (2025-04-30) | Q2 FY2026 (2025-07-31) | Q3 FY2026 (2025-10-31) | Q1 FY2027 (2026-04-30) | Q2 FY2027 (2026-07-31) | | --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | | Diluted shares (weighted) | millions of shares | [302](/filings/0001585521-23-000249.md) | [304](/filings/0001585521-24-000094.md) | [306](/filings/0001585521-24-000181.md) | [310](/filings/0001585521-24-000260.md) | [315](/filings/0001585521-25-000090.md) | [314](/filings/0001585521-25-000141.md) | [314](/filings/0001585521-25-000202.md) | [313](/filings/0001585521-26-000071.md) | [308](/filings/0001585521-26-000121.md) | [305](/filings/0001585521-25-000202.md) | [300](/filings/0001585521-26-000071.md) | [300](/filings/0001585521-26-000121.md) | - Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:43 ET. No prices; not investment advice.